EPS for Spark Therapeutics, Inc. (ONCE) Expected At $-0.45; Walgreens Boots Alliance, Inc. (WBA) Had 15 Analysts Last Week

April 17, 2018 - By Lawrence Diaz

Walgreens Boots Alliance, Inc. (NASDAQ:WBA) Logo

Analysts expect Spark Therapeutics, Inc. (NASDAQ:ONCE) to report $-0.45 EPS on May, 8.They anticipate $1.25 EPS change or 73.53% from last quarter’s $-1.7 EPS. After having $-1.73 EPS previously, Spark Therapeutics, Inc.’s analysts see -73.99% EPS growth. The stock increased 4.99% or $3.88 during the last trading session, reaching $81.67. About 360,883 shares traded. Spark Therapeutics, Inc. (NASDAQ:ONCE) has risen 21.52% since April 17, 2017 and is uptrending. It has outperformed by 9.97% the S&P500.

Among 24 analysts covering Walgreens Boots Alliance (NASDAQ:WBA), 15 have Buy rating, 1 Sell and 8 Hold. Therefore 63% are positive. Walgreens Boots Alliance had 58 analyst reports since August 24, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, October 24 by Mizuho. The rating was maintained by Needham with “Buy” on Monday, July 17. The stock of Walgreens Boots Alliance, Inc. (NASDAQ:WBA) has “Buy” rating given on Wednesday, June 21 by Jefferies. On Thursday, September 1 the stock rating was maintained by Credit Suisse with “Outperform”. Morgan Stanley downgraded the shares of WBA in report on Friday, October 6 to “Equal-Weight” rating. Credit Suisse maintained Walgreens Boots Alliance, Inc. (NASDAQ:WBA) rating on Monday, July 18. Credit Suisse has “Outperform” rating and $82.51 target. The firm has “Equal-Weight” rating given on Thursday, March 10 by Barclays Capital. The firm has “Buy” rating by Loop Capital Markets given on Thursday, August 24. As per Wednesday, October 28, the company rating was upgraded by RBC Capital Markets. The stock of Walgreens Boots Alliance, Inc. (NASDAQ:WBA) has “Buy” rating given on Thursday, October 29 by S&P Research. See Walgreens Boots Alliance, Inc. (NASDAQ:WBA) latest ratings:

02/04/2018 Broker: Scotia Capital Rating: Buy New Target: $91.0000 Maintain
28/03/2018 Broker: RBC Capital Markets Rating: Buy New Target: $88.0000 Maintain
28/03/2018 Broker: Guggenheim Rating: Buy New Target: $80.0000 Maintain
08/03/2018 Broker: Barclays Capital Rating: Equal-Weight New Target: $76 Initiates Coverage On
27/02/2018 Broker: Bank of America Rating: Hold New Target: $76.0
16/02/2018 Broker: RBC Capital Markets Rating: Buy New Target: $94.0 Maintain
13/02/2018 Broker: Loop Capital Markets Rating: Buy New Target: $90.0 Maintain
24/01/2018 Broker: Mizuho Rating: Buy New Target: $87.0 Maintain
09/01/2018 Broker: Needham Rating: Buy New Target: $88.0 Maintain
04/01/2018 Broker: Robert W. Baird Rating: Buy New Target: $82.0 Maintain

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company has market cap of $3.04 billion. The Company’s products include voretigene neparvovec, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or biallelic mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. It currently has negative earnings. The company's products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A.

Among 25 analysts covering Spark Therapeutics (NASDAQ:ONCE), 16 have Buy rating, 2 Sell and 7 Hold. Therefore 64% are positive. Spark Therapeutics had 68 analyst reports since August 21, 2015 according to SRatingsIntel. The stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) has “Buy” rating given on Monday, October 5 by Roth Capital. The rating was initiated by Stifel Nicolaus with “Buy” on Friday, September 2. The rating was downgraded by Leerink Swann to “Hold” on Tuesday, December 12. Cowen & Co maintained it with “Buy” rating and $85.0 target in Wednesday, January 3 report. The company was initiated on Thursday, June 2 by Jefferies. The stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) earned “Buy” rating by Cantor Fitzgerald on Friday, June 3. The firm has “Buy” rating by Jefferies given on Tuesday, July 11. The rating was maintained by Mizuho with “Buy” on Thursday, March 29. The firm earned “Hold” rating on Thursday, December 14 by Goldman Sachs. The rating was initiated by Mizuho on Monday, February 12 with “Buy”.

Investors sentiment decreased to 1.43 in Q4 2017. Its down 1.51, from 2.94 in 2017Q3. It dived, as 41 investors sold Spark Therapeutics, Inc. shares while 26 reduced holdings. 41 funds opened positions while 55 raised stakes. 35.76 million shares or 6.30% more from 33.64 million shares in 2017Q3 were reported. Blackrock Incorporated has invested 0.01% in Spark Therapeutics, Inc. (NASDAQ:ONCE). D E Shaw Inc accumulated 37,398 shares. Pictet Asset Ltd stated it has 0.02% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Wells Fargo Mn owns 253,563 shares. Federated Invsts Inc Pa stated it has 0.27% of its portfolio in Spark Therapeutics, Inc. (NASDAQ:ONCE). Fil Ltd owns 87,218 shares. Guggenheim Cap Ltd Liability Co holds 64,219 shares or 0.01% of its portfolio. Sei Investments Com holds 0% of its portfolio in Spark Therapeutics, Inc. (NASDAQ:ONCE) for 129 shares. Manufacturers Life Ins The reported 21,428 shares stake. Kistler reported 370 shares or 0.01% of all its holdings. California State Teachers Retirement Sys reported 43,567 shares or 0% of all its holdings. Lord Abbett & Ltd Llc accumulated 296,892 shares. Japan-based Sumitomo Mitsui Asset Management Communications Ltd has invested 0.02% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Fincl Architects stated it has 0% of its portfolio in Spark Therapeutics, Inc. (NASDAQ:ONCE). Clearbridge Ltd Limited Liability Company accumulated 687,444 shares or 0.03% of the stock.

The stock decreased 0.71% or $0.47 during the last trading session, reaching $65.75. About 3.97 million shares traded. Walgreens Boots Alliance, Inc. (NASDAQ:WBA) has declined 21.06% since April 17, 2017 and is downtrending. It has underperformed by 32.61% the S&P500.

Walgreens Boots Alliance, Inc. operates as a pharmacy-led health and wellbeing company. The company has market cap of $65.20 billion. It operates through three divisions: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. It has a 16.48 P/E ratio. The Retail Pharmacy USA segment sells prescription drugs and an assortment of general merchandise, including non-prescription drugs, beauty products, photo finishing, seasonal merchandise, greeting cards, and convenience foods through its retail drugstores and convenient care clinics.

Spark Therapeutics, Inc. (NASDAQ:ONCE) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>